source
- Moderna maintains 10% growth target despite Phase 3 norovirus missModerna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUS…BioSpace · 3h ago↗ source
- Sanofi CEO pledges deeper review of late-stage pipeline before Phase 3 movesSanofi's new chief executive, Belén Garijo, announced that the company will examine its late-stage pipeline more closely. The goal is to ensure that data from Phase 2 (or Phase 1b, depending on th…
- Biogen beats revenue expectations, lifts investor confidence with 3% sales rise